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ABSTRACT 
 
Skeletal metastasis occurs in around 75% of advanced breast cancers, with the disease 
incurable once cancer cells disseminate to bone, but there remains an unmet need for 
biomarkers to identify patients at high risk of bone recurrence. This study aimed to 
identify such a biomarker and to assess its utility in predicting response to adjuvant 
zoledronic acid.   
 
We used quantitative proteomics (SILAC-MS), to compare protein expression in a 
bone-homed variant (BM1) of the human breast cancer cell line MDA-MB-231 with 
parental non-bone-homing cells to identify novel biomarkers for risk of subsequent 
bone metastasis in early breast cancer.  SILAC-MS showed that Dedicator of 
cytokinesis protein4 (DOCK4) was upregulated in bone-homing BM1 cells, 
confirmed by Western blotting. BM1 cells also had enhanced invasive ability 
compared with parental cells which could be reduced by DOCK4-shRNA.   
In a training Tissue Microarray (TMA) comprising 345 patients with early breast 
cancer, immunohistochemistry followed by Cox regression revealed that high 
DOCK4 expression correlated with histological grade (p=0.004) but not oestrogen 
receptor status (p=0.19) or lymph node involvement (p=0.15). A clinical validation 
TMA used tissue samples and the clinical database from the large AZURE adjuvant 
study (n=689). Adjusted Cox regression analyses showed that high DOCK4 
expression in the control arm (no zoledronic acid) was significantly prognostic for 
first recurrence in bone (HR 2.13, 95%CI 1.06-4.30, p=0.034).  No corresponding 
association was found in patients who received zoledronic acid (HR 0.812, 95%CI 
0.176-3.76, p=0.790), suggesting that treatment with zoledronic acid may counteract 
the higher risk for bone relapse from high DOCK4-expressing tumours.  
Page 4 of 52
http://mc.manuscriptcentral.com/jpath
The Journal of Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
4 
 
 
High DOCK4 expression was not associated with metastasis to non-skeletal sites 
when these were assessed collectively. In conclusion, high DOCK4 in early breast 
cancer is significantly associated with aggressive disease and with future bone 
metastasis and is a potentially useful biomarker for subsequent bone metastasis risk.  
 
 
Keywords: DOCK4; Bone metastasis; breast cancer; biomarker; proteomics 
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INTRODUCTION 
Despite substantial progress in early detection and treatment, breast cancer still 
accounts for 15% of female cancer-related deaths, with skeletal metastasis occurring 
in approximately 75% of patients with advanced disease [1].  Relapse in bone 
typically occurs years after apparently successful treatment of early breast cancer and 
a period of tumour dormancy.  Bone-targeted agents such as bisphosphonates [2] and 
denosumab [3] are widely used to treat the skeletal complications of established bone 
metastases, but have also recently been the focus of several large adjuvant studies in 
early breast cancer to assess their potential to reduce the frequency of relapse in bone 
and subsequent breast cancer mortality.  The phase III AZURE trial (BIG01/04-
ISRCTN79831382) recruited 3360 patients with stage II/III breast cancer randomised 
(1:1) to 5 years of standard adjuvant therapy alone (control) or standard therapy with 
zoledronic acid (zoledronate[4].    Although there was no significant difference in 
invasive disease-free survival in the overall population, zoledronate improved disease 
outcomes for women who were >5 years postmenopausal at diagnosis and a meta-
analysis of 26 randomised trials (N=18,766), demonstrated that bone recurrences 
(HR=0.72; 95%CI 0.60, 0.86, 2p=0.0002) and breast cancer deaths (HR 0.82; 95%CI 
0.73, 0.93, 2p=0.002) were reduced by adjuvant bisphosphonates in post-menopausal 
women [5].  Breast cancer practice has changed as a result of these studies, but they 
also highlight the unmet need for biomarkers to identify patients with early breast 
cancer who are most at risk of developing bone recurrence, thus permitting tailoring 
of treatment to patients most likely to benefit and sparing patients who would not 
benefit, from potential complications [6]. Tissue samples from AZURE trial patients 
and the associated clinical database, prospectively designed to support biomarker 
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studies, offer a major opportunity for clinical validation of novel potential biomarkers 
for bone metastasis and other disease-related outcomes. 
 
Proteomic studies are yielding key information about breast cancer metastasis to bone 
[7-9] and, in a recent proteomics-based study, validated in 571 patients, we showed 
that the proteins CAPG and GIPC1 had both prognostic and predictive potential as 
biomarkers of bone metastasis [10].  In the current study, we hypothesized that 
proteins, identified by proteomics and up-regulated in breast cancer cells which have 
a propensity to home to bone, would be potential biomarkers for metastasis and could 
play key mechanistic roles in the process of metastatic dissemination to bone.   
 
MATERIALS AND METHODS 
 
Proteomic studies (Further details to those below are given in the text and in Figure 
S1 of Supporting Information)   
Cell culture and SILAC (Stable Isotope Labelling by Amino acids in Cell culture)  
The human breast cancer cell line MDA-MB-231 (“PCC”, parental control cells, 
obtained originally from ATCC) and a bone-homing variant (“BM1”, bone metastatic 
cells) [11] (the latter supplied by Prof. Joan Massague, Sloan-Kettering Institute, New 
York), were used in a ‘classical’ SILAC experiment [12,13].  PCC and BM1 cells 
were cultured in ‘heavy’ SILAC medium and ‘light’ medium for ~10 doublings to 
ensure >95% isotope label incorporation (Heavy media), and all cells were used 
within 10 doublings.  ‘Heavy’ SILAC media consisted of DMEM containing L-
arginine (
13
C6, 
15
N4) and L-lysine (
13
C6, 
15
N2) (R10K8, DMEM-15, Dundee Cell 
Products, Dundee, UK) supplemented with dialysed bovine serum (D-FBS100, 
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Dundee Cell Products, Dundee, UK).  ‘Light’ media was DMEM but without the 
heavy isotopes (R0K0).  
 
LC-MS/MS 
Equal amounts of protein (40 µg) from light and heavy labelled samples were 
combined, reduced, alkylated, and separated on a 1-D SDS-PAGE gel.  LC-MS-MS 
was performed by Dundee Cell products, Dundee, Scotland, UK.  Ten slices of the 
gel-resolved proteins were cut and proteins were digested to peptides using trypsin.  
Tryptic peptides were separated using a nanoflow LC-System coupled to an LTQ-
Orbitrap mass spectrometer (ThermoFisher Scientific).   
Quantitation and bioinformatics analysis 
Quantitation was performed using the software Max Quant 
(http://www.maxquant.org/downloads.htm), with peptide ratios calculated for each 
arginine- and/or lysine-containing peptide as the peak area of labelled arginine/lysine 
divided by the peak area of non-labelled arginine/lysine for each single-scan mass 
spectrum.  Peptide ratios for all arginine- and lysine-containing peptides sequenced 
for each protein were averaged.  Data output from Max Quant were analysed further 
using Excel and R (v. 3.2, http://www.r-project.org/) to select differentially expressed 
proteins.  
Western blotting 
The differential expression of DOCK4, and confirmation of DOCK4 knockdown, was 
assessed in cell lysates using Western blotting and an infra-red (IR) immunodetection 
system (LI-COR Biosciences), as well as by Enhanced ChemiLuminescence (ECL).  
Primary antibodies used were:  DOCK4 (Abcam ab56743, mouse 
monoclonal,0.1µg/mL); beta-tubulin (Abcam ab6046, rabbit polyclonal, 1/5000 
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dilution).  Secondary antibodies were:  #925-68070 IRDye 680RD goat anti-mouse 
IgG (H+L), LI-COR Biosciences, 1/5000 dilution, for detection of DOCK4 in the 
700nm channel (red); #925-32211 IRDye 800CW goat anti-rabbit IgG (H+L), LI-
COR Biosciences,1/5000 dilution, for detection of beta-tubulin in the 800nm channel 
(green). For ECL secondary antibodies were Goat-anti-mouse-HRP (Abcam, ab 6789) 
and goat anti-rabbit-HRP (Abcam, Ab6721, both 1:2,500). Normalised densitometric 
data from six replicate runs of the fluorescent-antibody immunoprobed samples, (and 
three blots from the ECL-visualized samples), were tested for significance using 
Student’s t-test. 
 
Generation of cell lines with stable DOCK4 knockdown and 3D invasion assay 
 
DOCK4 expression was knocked down in the BM1 and PCC cell lines by lentiviral 
delivery of a validated shRNA targeting DOCK4 (shR), with the use of an empty 
vector (cv) as control [14]. Untransduced, wild-type (wt) cells were also studied as 
control.  Inclusion of a GFP marker protein within the lentiviral vectors enabled 
FACS separation of vector-bearing clones and subsequent culture of pure cell 
populations.  Infected cells were selected by FACS sorting 48 hrs after lentiviral 
infection.  Confirmation of knockdown of DOCK4 protein expression was carried out 
by Western blotting as described above.  Quantification of the blots was performed by 
densitometric scanning.  
To study the effects of reduced expression of DOCK4 protein in PCC and BM1, an 
invasion assay was carried out using the IncuCyte platform (Essen BioScience) 
following the manufacturer’s instructions for a ‘scratch-wound’ procedure.  Briefly, 
triplicate wells of an ImageLock 96-well plate (Essen BioScience 4379) were over-
laid with thin Matrigel onto which wt, cv, and shR cells for PCC and BM1 were 
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seeded (50k cells/well and 100k cells/well, respectively), and a homogenous scratch 
was created using the Incucyte WoundMaker tool when the cell monolayer was 
confluent.  Cell invasion was assessed by measuring the closure of the scratch 
introduced on the confluent cell monolayer.  Experiments were performed in triplicate 
using independent cultures of cells.  Data were analysed using IncuCyte software 
and Excel.  
 
Patients, samples and immunohistochemistry: 
All analyses on patient samples were performed with Ethics approval (Leeds training 
set, 06/Q1206/180; AZURE validation set 55/03/182).   
Initial studies of DOCK4 expression were performed in a training TMA comprising 
345 specimens with available tumour type, grade, ER, lymph node (LN) and overall 
survival (OS) data, from breast tumours diagnosed at the Leeds Teaching Hospitals 
NHS Trust (1987 – 2005).  Samples were stained with a rabbit polyclonal DOCK4 
antibody (1:100, Bethyl Laboratories Inc;A302-263A) and corroborated in a smaller 
cohort with a mouse monoclonal antibody (1:50, Abcam;Ab56743).   
The main analyses for correlations with risk of bone metastasis were performed on 
TMAs constructed from primary tumours from a sub-set of patients within the overall 
AZURE trial (n = 689). Due to the relatively high prevalence of bone metastatic 
outcomes and the long follow-up (median 84 months [interquartile range 66-93]), 
these TMAs provide an excellent resource for validation of protein biomarkers 
emerging from our proteomics studies.  Protein expression was assessed using the 
Bethyl DOCK4 antibody (A302-263A). DOCK4 specificity for this antibody was 
confirmed by immunohistochemistry using FFPE cell pellets from BM1 cells with 
and without DOCK4 knockdown (Figure S2, Supporting Information). Full gel 
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images for the antibodies using ECL as the visualization method with use of positive 
and negative control cell-lines are included (Figure S3, Supporting Information).    
 
Digital images were created using a digital scanner (Aperio Scan Scope XT).  
Cytoplasmic staining assessment in the invasive margins of primary breast tumours 
was carried out independently by two trained operators, blinded to outcome data, 
under the supervision of an experienced breast histopathologist (AMH) who also 
adjudicated discrepant scores and the level of agreement of the two scores was 
measured using Cohen’s kappa coefficient.  All scores were based upon intensity of 
staining and not the number of positive cells.  Staining intensity was ranked based on 
a three tier ordinal categorical system used to rank the tumours based on intensity of 
cytoplasmic staining [15,16] where 1 = weak staining; 2 = moderate, easily perceived 
staining; 3 = strong/intense staining , i.e. the scoring was based on staining intensity 
only.  
 
Statistical analyses  
  
All immunohistochemical analyses followed REMARK guidelines [17]. Statistical 
analyses evaluated the associations between protein expression and relevant clinical 
and pathological variables (e.g. ER/PR/HER2 status) using Fisher’s Exact test 
(categorical variables) and the Kruskal-Wallis test (continuous variables), before 
assessing prognostic and predictive associations with time-to-event data (time to first 
distant recurrence, time to first skeletal recurrence, time to first non-skeletal 
recurrence) using Cox proportional hazards regression, the Kaplan-Meier estimate of 
the survival function and the log-rank test.  Time to first distant recurrence was 
defined as the time from the date of randomization to the date of the distant 
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recurrence.  In analyses, other types of events were censored, e.g. if a local recurrence 
occurred prior to any distant recurrence, the patient would be censored at the date of 
the local recurrence.  Time to first skeletal recurrence and first non-skeletal recurrence 
were defined similarly.  Time to first skeletal recurrence irrespective of all other 
previous recurrences was also investigated.  Time to event analysis was first 
performed within treatment arms to identify prognostic associations with the 
biomarkers.  The predictive heterogeneity of effect between treatment arms for time 
to distant events was assessed in multivariable analysis by including an interaction 
term in the Cox proportional hazard regressions for treatment arm and biomarker 
(while adjusting for systemic therapy plan, ER status and lymph node involvement).  
All significance tests were two-sided and were designated significant at the 5% level. 
 
 
RESULTS 
 
Proteomic identification of proteins specifically associated with breast cancer 
bone metastasis   
Proteins identified in the ‘forward’ and ‘reciprocal’ labelling experiments (Figure S1) 
were aligned and the most robust, highest quality, data were extracted for analysis 
using the following stringent selection criteria:  protein identified in both datasets; ≥2 
so-called razor+unique peptides assigned to identifications (clarifies assignment of 
protein identification); equal numbers of peptides and razor+unique peptides assigned 
to identifications. This resulted in 2006 proteins taken forward for analysis out of a 
total of 2999 identified in the complete data set (Full proteomic data are available on 
the publicly accessible database ORDA (https://orda.shef.ac.uk/)).   
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The aligned dataset was filtered further by using a 1.75-fold cut-off to distinguish 
change (up or down) in protein expression, resulting in 48 proteins up-regulated in 
BM1 relative to PCC cells (Table S1, Supporting Information).    These were 
prioritized for further study using literature evidence of relevance to bone metastasis, 
the magnitude of the differential expression fold change and evidence (where 
available) of non-association with lung metastases, based on correlation with our 
other proteomic datasets that included a MDA-MB-231 variant which specifically 
homes to lung (10, 11).  This allowed us to identify proteins likely to be involved in 
breast cancer metastasis to bone.  Consequently, four proteins had potential for further 
consideration: Dedicator of cytokinesis protein 4 (DOCK4, fold change 2.7), 
SerpinB2 (fold change 15.6), cell-division cycle protein 20 homolog (CDC20, fold 
change 3.7), and pericentrin (fold change 2.5). 
  
While all four have published evidence linking them to breast cancer we focused on 
DOCK4 for further investigation and clinical validation based on its published role in 
cell migration including breast cancer cell migration, metastasis [18-21] and tumour 
angiogenesis
 
(14), processes known to be integral to dissemination of tumour cells 
and development of bone metastases. Moreover, DOCK4 functions as a guanine 
nucleotide exchange factor for the GTPase Rac1, a key regulator of motility 
[14,19,20] and localises at actin-rich protrusions in migrating breast cancer cells [19], 
whilst SNPs within the promoter region of DOCK4 have been detected in breast 
cancer [22]. 
 
Confirmation of DOCK4 upregulation in BM1 cells 
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Analysis of DOCK4 expression levels by Western blotting in the BM1 and PCC cell-
lines showed a 2-fold increase in DOCK4 expression within the bone homing BM1 
cell-line compared to parental PCC (Figure 1A,C). Increased expression of DOCK4 
within BM1 cells was also confirmed using ECL-based visualization.    
 
DOCK4 is upregulated during breast cancer cell-motility 
There was significant knockdown of DOCK4 protein expression in the BM cell type 
following lentiviral delivery of DOCK4 shRNA (shR) compared with the empty 
vector (cv) control (Figure 1B,D).  In the wound healing assay, BM1 cells (control 
vector) had enhanced invasive ability compared with the PCC cells, with 13% and 
39% wound closure at 6 and 12h respectively, compared to 9 and 20% for PCC at 6 
and 12hrs (Figure 1E,F).  Invasion through Matrigel was reduced in cells with 
DOCK4 knockdown (shR) compared to control, with significant differences in wound 
closure observed for both cell types at 6 hours and 12 hours, and with a greater effect 
seen at 6 hrs.   
 
Association between DOCK4 expression and tumour grade in local breast 
tumour array 
DOCK4 expression was initially assessed in a local breast tumour array of 345 
unselected breast tumours (88% ductal, 9% lobular, 3% other) with patient data 
available on tumour grade (18% Grade 1, 44% Grade 2, 38% Grade 3) oestrogen 
receptor (ER), and axillary lymph node (LN) involvement. Examples of typical 
staining patterns are shown in Figure 2. Analysis revealed a significant association 
between DOCK4 expression and histological tumour type (p = 0.002) and tumour 
grade (p=0.004) with 86.4% Grade 3 and 77.3% grade 2 ductal carcinomas expressing 
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moderate/high DOCK4 (as opposed to 62.5% grade 1 carcinomas), but no association 
with ER status (positive versus negative, p=0.185) or LN status (involved versus not 
involved, p=0.15).  These data suggested that DOCK4 expression was associated with 
tumour aggressiveness and further supported our selection of DOCK4 for clinical 
validation in the AZURE patient cohort. 
 
Clinical validation of DOCK4 expression in breast cancer patients in the AZURE 
study. 
Patients. 
Independent scoring of stained TMAs by two trained operators (JW and SR) under the 
supervision of AMH yielded a Cohen’s kappa coefficient value of 0.86, signifying 
excellent agreement.  Possible associations between clinical outcomes and 
immunohistochemistry scores for DOCK4 were tested for 689 patients in the AZURE 
study (330 control arm, 359 zoledronate arm).  Demographic data for these patients 
are similar to those of the whole AZURE population (Table 1).  DOCK4 had no 
significant associations with age, lymph node involvement, ER status, tumour grade 
(though this approached significance, p = 0.062), menopausal status, systemic 
therapy, chemotherapy and statin use.  HER2 status was not a mandated assessment 
but was available for 307 participants.  DOCK4 was significantly associated with 
HER2 status with a smaller proportion of patients with low DOCK4 being HER2 
positive (P<0.001).  However, adjustment for HER2 status had no impact on 
subsequent statistical analyses in either control or zoledronate arms.       
 
AZURE patients: Association of DOCK4 expression with distant event recurrence. 
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Control arm. Initial analyses considered possible associations between DOCK4 
expression (scored as 1, 2 or 3) and disease-free survival (DFS) for distant recurrence 
components of DFS. Whilst we found no statistically significant association between 
DOCK4 and first event in non-skeletal sites, taken as a group (p = 0.08, Figure 3a) or 
in any distant site (p = 0.475, Figure 3d) higher DOCK4 was significantly associated 
with increased risk of developing first event as skeletal recurrence whether only in 
bone (p = 0.043, Figure 3c) or in bone and other distant sites concurrently (p = 0.033, 
Figure 3b).   
 
Subsequently, dichotomised TMA expression scores were used where high DOCK4 
expression (score of 3) was compared with low DOCK4 expression (score of 1 or 2).  
Using these categories, Kaplan-Meier estimates of the survival function for time to 
distant recurrence confirmed that high DOCK4 is significantly prognostic for first 
distant recurrence involving bone only (HR 2.1; 95% CI 1.09, 4.15, p = 0.024, Figure 
4a). For first distant event involving both skeletal and other site(s) concurrently, 
although the same trend was observed, the association did not reach significance (HR 
1.6; 95%CI 0.88, 3.05, p = 0.113, Figure 4c).  
 
Where the first distant event was in non-skeletal sites (taken as a group), the 
corresponding dichotomised analyses (Figure 4e), suggested a non-significant reduced 
risk of non-skeletal events with high DOCK4 (HR = 0.2; 95%CI 0.03, 1.51, p = 0.12). 
In the dichotomised analyses, we found no association between high DOCK4 and first 
skeletal event, whether or not other distant events had occurred first, (HR = 1.3; 
95%CI 0.73, 2.33, p = 0.373), suggesting that the inclusion of metastasis in other 
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sites, before eventual spread to bone, counters the significant association seen with the 
bone only analyses. 
 
Zoledronate arm.  
 In the zoledronate arm, dichotomised analyses revealed no association between 
DOCK4 and bone only distant events (HR 0.6; 95%CI 0.14, 2.62, p = 0.488, Figure 
4b), ie the increased risk of bone-only first event posed by high DOCK4 in the control 
arm was abolished by zoledronate. This suggests that DOCK4 may act as a predictive 
biomarker for prevention of bone metastases by zoledronate. This was confirmed by 
examining Kaplan-Meier plots for DOCK4 high and DOCK4 low comparing control 
and zoledronate patients for the various events (Supporting Information, Figure S5). 
Figure S5(b) clearly shows the reduction in bone metastasis-only risk as a first event 
(HR 0.1; 95% CI 0.03, 0.5, p=0.003) in patients with high DOCK4 treated with 
zoledronate.  
 
For the first event involving bone and other sites concurrently, there was no 
significant association seen in the zoledronate group (Figure 4d). 
 
Cox proportional hazards regressions adjusted for systemic therapy plan, ER status, 
HER2 status and lymph node involvement 
Control arm. Adjusted analyses (Table 2) confirmed that high DOCK4 expression 
was significantly prognostic for skeletal only events (HR 2.13, 95% CI 1.06, 4.30, p = 
0.034).  Similar analyses for first recurrence events involving the skeleton and other 
site(s) concurrently showed no significant association (HR 1.63, 95%CI [0.86, 3.12], 
p = 0.137; Table 2).  No significant association was found in these adjusted analyses 
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for non-skeletal distant events when assessed collectively. Analysis of relationships to 
other individual metastatic sites was not possible with this data-set.  
 
Zoledronate arm.  The significant prognostic effect of DOCK4 for skeletal only 
metastases seen in the control arm patients was not observed in the zoledronate arm 
(HR 0.812, 95%CI [0.18, 3.76], p = 0.790) (Table 2), suggesting again that the 
increased risk for skeletal metastasis in patients with high DOCK4 levels at baseline, 
may be counteracted by treatment with zoledronate.  This was tested formally by 
including an interaction term in the Cox proportional hazards regressions for 
treatment arm and DOCK4 level for time to first event, skeletal only.  These analyses 
suggested a predictive effect for treatment with zoledronate (HR 0.12 95%CI 0.03, 
0.56; likelihood ratio test p=0.063, [hazard ratio <1 indicates improvement with 
zoledronate]), though this did not reach significance. 
 
Overall survival and menopausal status 
As shown in Figure 4 (i) and (j) and Supplementary Figure S5 (i) and (j), although 
there appeared to be a trend towards high DOCK4 producing worse outcome, 
DOCK4, expression level did not impact significantly on overall survival in either the 
control or the zoledronate arms. When post-menopausal and pre-menopausal patients 
were analysed separately, although similar associations with bone metastasis to the 
full group were observed, there was a loss of statistical significance due to the smaller 
numbers involved. 
 
DISCUSSION 
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Breast cancer bone metastasis causes significant morbidity and biomarkers which can 
predict the development of bone metastases are badly needed. In this translational 
study, SILAC-MS-based comparison of bone homing and non-homing cell variants 
and functional in vitro work, coupled with rigorous clinical validation enabled us to 
identify DOCK4 as a potential biomarker for this purpose.   
 
Mechanistically, there have been few studies identifying differentially expressed 
proteins within breast cancer bone metastasis; as such the current study provides a 
novel perspective on homing of breast cancer to bone sites of distant relapse.  SILAC 
is an established proteomics approach, which gives quantitative information on the 
relative expression of proteins when comparing two or more cell types.  This 
approach was successful in terms of the overall numbers of proteins identified with 
high confidence in the total data set (n = 2999).   
 
Our discovery science used MDA-MB-231 and its bone homing variant BM1. The 
MDA-MB-231 cell line is regarded as ‘gold standard’ for this type of research as it 
was derived from a pleural effusion of a breast cancer patient with widespread 
metastasis, many years after resection of the primary tumour [23]. Furthermore, the 
validity of this approach has already been proven in our previous work in which the 
importance of the proteins CAPG and GIPC1 as biomarkers was discovered and 
subsequently clinically validated (10). Here, we focused on DOCK4, a key guanine 
nucleotide exchange factor (GEF) regulating the activation of the small GTPase Rac1 
(19,20,24,25).  DOCK4-mediated activation of Rac1 has been demonstrated to 
promote actin reorganization and the formation of lamellipodia at the leading edge of 
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breast cancer cells [19]  as well as the formation of lateral filopodia, and blood vessel 
lumen morphogenesis within tumour angiogenesis [14].   
 
DOCK4 was expressed in parental MDA-MB-231 cells (PCC), but was more 
abundant in the bone-homing variant (BM1).  DOCK4 knockdown inhibited the 
migration of both PCC and BM cell-lines with inhibition being greater at 6 hours than 
12 hours post assay-initiation, suggesting that DOCK4-mediated cell invasion may be 
important in the earlier stages of breast cancer cell-migration.  
However, enhanced cell-migration and invasiveness resulting from high DOCK4 
expression is only one aspect of the bone-homing cells which makes them bone 
homing. In particular, c-MAF targets and other proteins elevated in the bone homing 
cells might drive the bone-homing phenotype as well as DOCK4. Our observation 
that, in patients, high DOCK4 is specifically associated with first distant metastasis in 
bone, may be linked to these factors, including those in the bone micro-environment. 
Notably in this regard, the specific association of high DOCK4 with bone metastasis 
at any time, is lost once metastasis has occurred elsewhere. This presumably indicates 
the substantially altered metastatic environment influencing bone metastasis once 
non-bone metastases have occurred. Association with bone as first metastatic site is 
lost in zoledronate-treated patients suggesting that zoledronate treatment reduces the 
risk of bone metastasis to a level similar to that in non-high DOCK4 patients. 
 
This work has shown that DOCK4 has a similar prognostic and predictive profile to 
CAPG and GIPC1 for the prognosis of skeletal-only relapse within control arm 
patients. 
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DOCK4 was also similar to the previously discovered markers in not being predictive 
of non-skeletal recurrence events within control arm patients. Treatment with 
zoledronate abolished the association of high levels of all three of these proteins in 
development of skeletal-only metastasis.  
 
DOCK4 expression is induced by the cytokine transforming growth factor-β (TGFβ) 
acting via the Smad pathway, and this is a key step in TGFβ’s pro-metastatic effect 
[21]. GIPC1 is also a key scaffolding protein which functions to transmit signals from 
the TGFβ-receptor and its co-receptor endoglin to downstream Smad-phosphorylation 
[26]. TGFβ is a regulator of numerous steps within metastasis including intravasation, 
extravasation and cancer-cell survival at distant organ sites [27]. The transcription 
factor c-MAF has recently been identified as a key regulator of breast cancer bone 
metastasis [28,29]. c-MAF expression is induced by TGFβ and a recent patent 
application showed that DOCK4-expression correlates with MAF-expression within 
primary tumours [30]. Examination of our quantitative proteomic data set identified 
36 proteins also present in the c-MAF gene set (a panel of 109 genes in total). Within 
the 36 proteins quantified by proteomics, 15 proteins displayed the same change 
(increase or decrease of expression within bone-homing cells compared to parental 
cells) as the relevant gene transcripts in response to c-MAF expression. DOCK4 may 
therefore be a component of a protein panel which responds to elevated c-MAF 
expression within bone homing breast cancer cells.                         
 
As well as being a prognostic biomarker, our data also provide evidence that DOCK4 
is a potential predictive biomarker in terms of the treatment effect of zoledronate for 
bone as first metastatic site, since the addition of zoledronate appears to reduce the 
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risk of patients with high DOCK4 levels to that of patients with lower DOCK4 levels. 
There was also a substantial HR in favour of a treatment effect when an interaction 
term was included in the Cox proportional hazards regression, though this fell short of 
statistical significance and additional testing in a further patient cohort is needed 
before DOCK4 can be confirmed as a predictive biomarker. 
 
Our current studies are supported further through analysis of DOCK4 gene expression 
within a publicly available database where high DOCK4 transcript levels predicted 
distant bone metastatic spread of breast cancer (Figure S4, Supporting Information)   
  
 
Interestingly, DOCK4 was not prognostic for DFS in terms of metastasis at non-
skeletal sites, taken as a group (N=28). Indeed, data for the control arm in Figure 4 
and Table 2 (and in Figure S5) suggest that high DOCK4 may be associated with a 
reduction in the occurrence of non-skeletal metastasis, an effect which is not seen in 
the zoledronate arm. Whilst zoledronate is advantageous in terms of preventing 
skeletal metastasis in DOCK4 high patients, it may also remove a potentially 
advantageous effect for non-skeletal metastases.  Whilst our data do not point to any 
particular mechanistic explanation for this effect, it is possible that zoledronate may 
have effects other than on the skeleton and, in this respect, we note the negative 
impact of zoledronate on overall survival in pre-menopausal women recently 
reported, where in non-postmenopausal patients with MAF-positive tumours, 
zoledronate was associated with worse invasive-disease-free survival and overall 
survival [28]. Clearly, these factors need to be borne in mind in the consideration of 
DOCK4 as a predictive biomarker for zoledronate response in bone metastasis 
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prevention. DOCK4 may play a functional role in the process of breast cancer 
metastasis to the bone, as it was also previously shown to play a role in the process of 
extravasation of lung adenocarcinoma cells to the liver [21]. However, DOCK4 may 
not be necessary for metastasis to all secondary sites, so that other metastatic sites 
such as the lung, may not require elevated DOCK4 expression for metastasis. This 
may be related to the role of DOCK4 for cancer cell extravasation and vascular 
differences at different metastatic sites, or differential requirement for metastatic 
growth in different organ microenvironments. Because our analyses included non-
skeletal sites as a single group, they do not exclude the possibility of DOCK4 
association with a less common site for metastatic spread than the skeleton.  
 
There are some limitations to the current study. Although the number of patients 
available for analysis from the AZURE study considerably exceeds that required for 
statistical powering, there is currently no equivalent independent sample set available 
for further validation.  Also, breast cancer metastasis to bone involves numerous 
autocrine and paracrine signalling events [31], and these and the directionality and 
recruitment of key signalling pathways that migration involves, is clearly not 
replicated within the invasion assay used in the current study.  More complex tools to 
assess this are not currently available. 
 
Further studies of the mechanistic role of DOCK4 in breast cancer bone metastasis 
and implications for pharmacological inhibition is justified by our work.  In addition, 
the potential for the DOCK4 mediated signalling pathway to function as a target for 
pharmacological inhibition within breast cancer bone metastasis is an exciting 
possibility. This study suggests that DOCK4 may have clinical utility as a potential 
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prognostic biomarker for assessment of risk of cancer progression to the skeleton, 
possibly in combination with other biomarkers, since the specificity and sensitivity of 
a biomarker test can be improved by the incorporation of multiple markers into a 
diagnostic/prognostic panel of markers [27]. DOCK4 may therefore form part of a 
future panel-based test (possibly including CAPG, GIPC1 and the MAF gene [28]) 
used for informing patient treatment options.  Future validation studies of DOCK4 as 
a biomarker of bone metastasis in other datasets with denosumab treatment or other 
use of bisphosphonates would be useful, if samples from such datasets become 
available in the future.  
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A file has been uploaded for on-line access only containing Supporting Information. 
This file contains further details on the methods used in this study, and further 
relevant data in table and figure format. This table (Table S1) and the figures (Figures 
S1-S5) have been cited in the main article. 
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Legends to Figures 
 
Figure 1.  Schematic showing the key steps in the SILAC proteomic 
approach used.   
MDA-MB-231 (MDA231) and bone-homed variant (BM) cell lines were incubated 
with media containing ‘heavy’ and ‘light’ isotopically labelled amino acids arginine 
(R) and lysine (K).  The heavy medium contained [
13
C6, 
15
N4]-L-Arginine and [
13
C6, 
15
N2]-L-Lysine, i.e. stable isotopes of [
12
C6, 
14
N4]-L-Arginine and [
12
C6, 
14
N2]-L-
Lysine, respectively.  Two experiments were performed involving ‘forward’ and 
‘reverse’ labelling (reciprocal labelling) in which the cell lines were incubated in both 
media types and then combined in heavy:light pairs in a 1:1 ratio (based on extracted 
protein assay) prior to separation by molecular weight using 1-DE.  The entire lane of 
gel-separated proteins was cut into equal slices (n=10).  The proteins in each gel slice 
were reduced to peptides by enzymatic digestion (using trypsin) and were further 
separated using high-performance liquid chromatography (HPLC) and analysed using 
high-resolution mass spectrometry (MS) 
 
Figure 1:  A and C.  Higher DOCK4 expression in BM cell type; B and D  
Knock-down of DOCK4 expression by shRNA.  DOCK4 was confirmed to be of 
higher expression in BM1 cell type by Western blotting (2.0-fold induction, p = 
0.027), and 81% and 88% knock-down of DOCK4 protein expression was achieved in 
PCC and BM1 cells, respectively.  Representative whole-gel lane images are shown.  
wt = wild type (no vector involvement); cv = control vector; sh = shRNA. 
E and F:  Invasion assay.  The ability of PCC and BM1 cells to move through 
Matrigel™ matrix was assessed using a scratch-wound assay.  Significant differences 
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between the control vector and DOCK4 knock-down cells were seen at the 6 and 12hr 
time points.   
 
Figure 2. Examples of staining profiles for DOCK 4 in patients from the 
AZURE study. 
Composite of differential protein expression intensities for DOCK4 protein 
expression as revealed by IHC and visualised at magnification x 20.  The scoring is 
based on the intensity of staining in the cytoplasmic compartment in the tumour cells 
only.  Scale bar = 200µm. 
 
Figure 3. Association of DOCK4 with DFS events. Kaplan-Meier estimates of 
the relationship between expression of DOCK4 and (a) non-skeletal DFS events (b) 
skeletal DFS events (where other distant events may have been recorded at the same 
time);  (c) solely skeletal DFS events (where no other distant event was recorded at 
the same time) and (d) any DFS events (where first event was recorded at any distant 
site) in patients in the control arm of the AZURE trial (n = 434). P-value is from the 
logrank test for testing equality of survival functions. 
 
Figure 4. Univariate associations of distant recurrence outcomes with biomarker 
expression in control and zoledronate arms. (Estimates are from Cox proportional 
hazards regressions) Kaplan-Meier estimates of the survival function for time to 
distant recurrence (DR) and overall survival for control and zoledronate arms. 
Numbers 1 to 3 refer to the DOCK4 staining intensity scores. These were 
dichotomised, ie DOCK4 low (1 and 2); DOCK4 high (3).  Comparisons shown to be 
significant are also significant in analyses adjusting for the effect of systemic therapy 
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plan, ER status and lymph node involvement. (a) and (b): Skeletal only; (c) and (d): 
skeletal and other; (e) and (f): Non-skeletal; (g) and (h): First skeletal irrespective of 
whether other distant events have occurred previously (ie bone metastasis-free 
survival).  (i) and (j): Overall Survival (OS). P-values refer to the logrank test. For 
definitions of non-skeletal, skeletal and other and skeletal only see legend to Table 1. 
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Table 1: Characteristics of the patients whose tissue was assessed on TMAs in 
this study (as at baseline on the AZURE study) and first disease-free survival 
(DFS) events.  Non-skeletal (first distant recurrence event does not include any 
skeletal component);  Skeletal and other (first distant recurrence event reported 
includes both skeletal and other sites of metastasis, as well as skeletal only); Skeletal 
only (first distant recurrence event only skeletal - this group is a subset of those 
classified as skeletal and other). 
 
Characteristic DOCK4 dataset Full AZURE trial population 
zoledronate 
(n=359) 
Control 
(n=330) 
zoledronate 
(N=1681) 
Control 
(n=1678) 
 
Age (years) Median (range) 
 
50 (26, 75) 
 
51 (32, 79) 
 
51 (20-89) 
 
51 (21, 89) 
 
Axillary lymph nodes - no. (%)     
0 4 (1.2) 4 (1.2) 29 (1.7) 32 (1.9) 
1-3 223 (67.6) 223 (67.6) 1041 (61.9) 1032 (61.5) 
≥4 103 (31.2) 103 (31.2) 604 (35.9) 608 (36.2) 
Tumour stage - no. (%)     
T1 115 (32.0) 116 (35.2) 542 (32.2) 523 (31.2) 
T2 196 (54.6) 163 (49.4) 851 (50.6) 867 (51.7) 
T3 37 (10.3) 43 (13) 227 (13.5) 228 (13.6) 
T4 11 (3.1) 8 (2.4) 58 (3.5) 59 (3.5) 
     
Histological grade - no. (%)     
1 26 (7.2) 23 (7.0) 145 (8.6) 140 (8.3) 
2 144 (40.1) 130 (39.4) 731 (43.5) 708 (42.2) 
3 187 (52.1) 174 (52.7) 765 (45.5) 787 (46.9) 
Not specified  3 (0.9)   
Missing 2 (0.6)    
ER status - no. (%)     
ER positive 255 (77.3) 255 (77.3) 1319 (78.5) 1316 (78.4) 
ER negative 80 (22.3) 72 (21.8) 349 (20.8) 355 (21.2) 
ER unknown 1 (0.3) 3 (9) 13 (0.8) 7 (0.4) 
PR status - no. (%)     
PR positive 126 (35.1) 102 (30.9) 725 (43.1) 698 (41.6) 
PR negative 63 (17.5) 73 (22.1) 382 (22.7) 424 (25.3) 
PR unknown 169 (47.1) 153 (46.4) 571 (34.0) 548 (32.7) 
Missing 1 (0.3) 2 (0.6)   
HER2 status - no. (%)     
HER2 positive 38 (10.6) 48 (12.7) 192 (11.4) 223 (13.3) 
HER2 negative 106 (29.5) 84 (26.0) 648 (38.5) 603 (35.9) 
HER2 unknown/not measured 209 (58.3) 197 (61.2) 831 (49.5) 843 (50.1) 
Missing 6 (1.7) 1 (0.3)   
Menopausal status - no. (%)     
Pre-menopausal 167 (46.5) 151 (45.8) 751 (44.7) 752 (44.8) 
≤ 5 years since menopause 53 (14.8) 54 (16.4) 247 (14.7) 244 (14.5) 
> 5 years since menopause 112 (31.2) 97 (29.4) 519 (30.9) 522 (31.1) 
Menopausal status unknown 27 (7.5) 28 (8.5) 164 (9.8) 160 (9.5) 
     
Planned systemic therapy - no. 
(%) 
    
Endocrine therapy alone 24 (6.7) 17 (5.2) 76 (4.5) 74 (4.5) 
Chemotherapy alone 79 (22.0) 72 (21.8) 362 (21.5) 360 (21.5) 
Endocrine therapy plus 
chemotherapy 
256 (71.3) 241 (73.0) 1243 (73.9) 1243 (74.1) 
Type of chemotherapy     
Anthracyclins - no. (%) 328 (91.4) 307 (93.0) 1567 (97.6) 1564 (97.6) 
Taxanes - no. (%) 48 (13.4) 41 (12.4) 390 (24.3) 385 (24.0) 
Timing of chemotherapy     
Neo-adjuvant 14 (3.3) 11 (3.3) 104 (6.5) 104 (6.5) 
Post-operative 345 (96.7) 319 (96.7) 1501 (93.5) 1499 (93.5) 
Statin use - no. (%) 19 (5.3) 15 (4.5) 97 (5.8) 101 (6.0) 
Type of first disease-free 
survival event - no. (%) 
    
Loco-regional recurrence 26 (7.2) 17 (5.2) 79 (4.7) 78 (4.7) 
Distant recurrence  68 (18.9)  74 (22.4) 332 (19.8) 341 (20.3) 
Distant and loco-regional 
recurrence 5 (1.4) 3 (0.9) 
18 (1.1) 21 (1.3) 
Death without prior recurrence 11 (3.1) 13 (3.9) 53 (3.2) 44 (2.6) 
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First distant recurrence is 
nonskeletal - no. (%)   
  
 46 (12.8) 28 (8.5) 194 (11.5) 165 (9.8) 
     
First distant recurrence 
includes skeletal and other - 
no. (%)   
  
 27(7.5) 49 (14.8) 156 (9.3) 197 (11.7) 
     
First distant recurrence is 
skeletal only - no. (%)   
  
 16 (4.5) 38 (11.5) 97 (5.8) 140 (8.3) 
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Table 2 Cox regression analysis for associations between protein IHC and distant 
recurrence events by AZURE trial arm.  
Reference category in each multivariable model is DOCK4 low (1 or 2) Comparisons 
shown to be significant are also significant in analyses adjusting for the effect of 
systemic therapy plan, ER status, HER2 status and lymph node involvement. Time to 
first bone metastasis is defined as time to the first skeletal distant recurrence, 
irrespective of whether other distant recurrence has occurred earlier (ie bone 
metastasis-free survival).   For definitions of non-skeletal, skeletal plus other and 
skeletal only, see legend to Table 1. NB: n = number of events and N = number at 
risk. 
 
 
  Standard Treatment Standard Treatment + zoledronic Acid 
  N 
(at 
risk) 
n 
(events) 
HR 
(95% CI) 
p-
value 
N 
(at 
risk) 
n 
(events) 
HR 
(95% CI) 
p-
value 
Nonskeletal 
distant 
recurrence 
Unadj 330 28 0.154 
[0.021,1.131] 
0.066 359 46 1.162 
[0.577,2.342] 
0.674 
 Adj 329 28 0.201 
[0.027,1.506] 
0. 118 353 46 0.999 
[0.478,2.086] 
0.997 
          
Distant 
recurrence 
including 
skeletal 
Unadj 330 49 1.642 
[0.883,3.052] 
0.117 359 27 0.96 
[0.363,2.535] 
0.934 
 Adj 329 49 1.634 
[0.855,3.121] 
0.137 353 26 0.999 
[0.336,2.967] 
0.998 
          
Skeletal 
only distant 
recurrence 
Unadj 330 38 2.121 
[1.085,4.148] 
0.028 359 16 0.595 
[0.135,2.619] 
0.493 
 Adj 329 38 2.133 
[1.058,4.304] 
0.034 353 16 0.812 
[0.176,3.756] 
0.79 
          
Bone 
metastasis 
at any time 
Unadj 330 62 1.302 
[0.728,2.328] 
0.374 359 49 0.81 
[0.38,1.728] 
0.586 
 Adj 329 62 1.344 
[0.734,2.46] 
0.338 353 47 0.882 
[0.387,2.012] 
0.765 
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Supporting Information. 
Further experimental details of proteomics methods 
Cell culture and SILAC (Stable Isotope Labelling by Amino acids in Cell culture)  
The human breast cancer cell line MDA-MB-231 (“PCC”, parental control cells, obtained 
originally from ATCC) and a bone-homing variant (“BM1”, bone metastatic cells) (1) (the 
latter supplied by Prof. Joan Massague, Sloan-Kettering Institute, New York), were used in a 
‘classical’ SILAC experiment‘ (2, 3). Quarterly Mycoplasma checks and annual STR 
profiling confirmed cell provenance.  PCC and BM1 cells were cultured in ‘heavy’ SILAC 
medium and ‘light’ medium for ~10 doublings to ensure >95% isotope label incorporation 
(Heavy media), and all cells were used within 10 doublings.  ‘Heavy’ SILAC media consisted 
of DMEM containing L-arginine (
13
C6, 
15
N4) and L-lysine (
13
C6, 
15
N2) (R10K8, DMEM-15, 
Dundee Cell Products, Dundee, UK) supplemented with dialysed bovine serum (D-FBS100, 
Dundee Cell Products, Dundee, UK).  ‘Light’ media was DMEM but without the heavy 
isotopes (R0K0).  Essentially, two experiments were performed involving ‘forward’ and 
‘reverse’ labelling (i.e. reciprocal labelling) in which the cell lines were incubated in both 
media types and then combined in heavy:light pairs in a 1:1 ratio (based on extracted protein 
amount) prior to separation by molecular weight using 1-DE.  For proteomic analysis, cells 
were extracted for total protein content using Laemmli buffer (S-3401 Sigma-Aldrich).   
LC-MS/MS 
Equal amounts of protein (40 µg) from light and heavy labelled samples were combined, 
reduced, alkylated, and separated on a 1-D gel.  LC-MS-MS was performed by Dundee Cell 
products, Dundee, Scotland, UK.  Ten slices of the gel-resolved proteins were cut and 
proteins were digested to peptides using trypsin.  Tryptic peptides were separated using a 
nanoflow LC-System coupled to an LTQ-Orbitrap mass spectrometer (ThermoFisher 
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Scientific).  Survey full scan MS spectra (m/z 300-1700) were acquired in the Orbitrap with a 
resolution of 60,000 at m/z 400 after accumulation of 1,000,000 ions.  The five most intense 
ions from the preview survey scan delivered by the Orbitrap were sequenced by collision 
induced dissociation (normalized collision energy = 40%) after accumulation of 5,000 ions 
concurrently to full scan acquisition in the Orbitrap.  Data were acquired using the Xcalibur 
software. 
Quantitation and bioinformatics analysis 
Quantitation was performed using the software Max Quant 
(http://www.maxquant.org/downloads.htm), with peptide ratios calculated for each arginine- 
and/or lysine-containing peptide as the peak area of labelled arginine/lysine divided by the 
peak area of non-labelled arginine/lysine for each single-scan mass spectrum.  Peptide ratios 
for all arginine- and lysine-containing peptides sequenced for each protein were averaged.  
Data output from Max Quant were analysed further using Excel and R (v. 3.2, http://www.r-
project.org/) to select differentially expressed proteins for consideration as candidates for 
further verification and validation. 
Western blotting 
The differential expression of DOCK4, and confirmation of DOCK4 knockdown, was 
assessed in cell lysates using Western blotting and an infra-red (IR) immunodetection system 
(LI-COR Biosciences) as well as by Enhanced Chemiluminescence (ECL).  The primary 
antibodies used were:  DOCK4 (Abcam ab56743, mouse monoclonal,0.1µg/mL; beta-tubulin 
loading control (Abcam ab6046, rabbit polyclonal, 1/5000 dilution.  Secondary antibodies 
were:  #925-68070 IRDye 680RD goat anti-mouse IgG (H+L), LI-COR Biosciences, 1/5000 
dilution, for detection of DOCK4 in the 700nm channel (red); #925-32211 IRDye 800CW 
goat anti-rabbit IgG (H+L), LI-COR Biosciences,1/5000 dilution, for detection of beta-
Page 36 of 52
http://mc.manuscriptcentral.com/jpath
The Journal of Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
tubulin in the 800nm channel (green).  Normalised densitometric data from six replicate runs 
of the immunoprobed samples were tested for significance using Student’s t-test. For ECL the 
secondary antibodies used were: goat-anti-mouse HRP (Abcam, Ab6789) and goat anti-
rabbit-HRP (Abcam, Ab 6721) both used a 1 in 2500 dilution followed by visualization with 
ECL-Reagent (Promega).  
Further experimental details of immunohistochemistry 
Bone homing MDA-MB-231 cells (BM1) were subjected to lentiviral transfection of either 
control plasmid (control vector) or plasmid expressing anti-DOCK4 miRNA (DOCK4 
miRNA) as described in the main manuscript, Materials and Methods. Cells were cultured in 
DMEM + 10% (v/v) FBS until confluent and then harvested by trypsinization, cells pelleted 
at 1000 x g and the cell pellet washed twice with PBS. Cell pellets were then resuspended in 
10% formalin in Neutral Buffered Saline and fixed for 48 hours at 4°C. In preparation for 
sectioning, 100µl of 10% (w/v) molten agarose was allowed to set in eppendorf tubes 
forming an agarose plug. Following fixation of the cells in 10% (v/v) formalin in neutral 
buffered saline they were pelleted at 1000 x g and then resuspended in 300µl (10% w/v) 
molten agarose. Cells in molten agarose were introduced into the pre-prepared Eppendorf 
tubes with 100µl agarose plugs and allowed to set overnight at 4°C. The next day cell-pellets 
were progressively dehydrated in graded alcohol followed by xylene and then finally molten 
wax treatment. Cell-pellets were embedded in wax blocks and sectioned at 5µm onto 
Superfrost Slides (Manufacturer: Menzel-Gläser), then dried for approximately 48 hours at 
37°C. Sections were dewaxed in xylene, and rehydrated in graded alcohol and then 
endogenous peroxidase-blocked with 10% (v/v) hydrogen peroxide. Antigen retrieval was 
done using citrate buffer (pH 6.0) using a microwave for 20 minutes. Sections were blocked 
in 10% (v/v) goat serum and then primary antibody (Bethyl anti-DOCK4 antibody, Cat No: 
A302-263A) added overnight at a dilution of 1 in 100. Sections were developed using 
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biotinylated secondary antibody (Vector labs) at a dilution of 1 in 200 for 1 hour. Sections 
were rinsed and developed using the Vector Labs ABC kit (Cat No: PK-6100, standard) for 
30 minutes. DAB was applied for 1 minute and then sections rinsed and counter stained with 
Gills Haematoxylin. Sections were then rehydrated with graded alcohols and mounted using 
DPX. Slides were scanned using a Pannoramic 250 slide scanner (3DHistech) and images 
analysed for DAB staining intensity within the QuPath software program.     
 
Testing antibody specificity: Western blotting:   
Total cell lysates from bone-homing MDA-MB-231 cells (BM1) and parental controls (PCC) 
were prepared in 1x Laemmli Sample Buffer. In addition cell lysates were also prepared from 
bone homing (BM1) cells following lentiviral transfection of either control vector or DOCK4 
miRNA). All cell-lysates were assayed for protein content using the Bio-Rad RC-DC protein 
assay kit. 50µg of total cell protein was loaded onto each lane of a 10-lane Bio-Rad Mini-
Protean 4-20% TGX SDS-PAGE gel and blotted onto nitrocellulose membrane. Following 
blocking of the membranes overnight at 4°C with 5% (w/v) milk powder in phosphate-
buffered saline (PBS) they were probed with either: Abcam anti-DOCK4 (ab56743) at a 
dilution of 1 in 3400 or the Bethyl anti-DOCK4 antibody (A302-263A) at a 1 in 2000 dilution 
for 1 hour. Blots were washed and secondary antibody applied (for Abcam ab56743, mouse 
secondary was applied and for Bethyl anti-DOCK4 a rabbit secondary, both secondaries were 
used at a 1 in 2500 dilution) for one hour. Blots were then washed with PBS-tween and 
developed with ECL-reagent (Promega, Cat. No: W1001) prior to exposure to x-ray film.               
Gene-expression analysis for DOCK4: 
Gene expression data for Wang et al (4) were obtained from the breastCancerVDX (5) 
Bioconductor package, and sample metadata from the GEO submission (GSE2034) was used 
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to determine which samples had metastasis to the bone. A recursive partitioning (RP) analysis 
(6) was performed to determine if the samples can be split into two groups based on the 
expression data of DOCK4. Difference in the time to metastasis in the two groups was then 
assessed using the “survival” R package (7).  
References for Supporting Information 
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Supplementary Table S1: Proteomic Results for up-regulated proteins within the 
SILAC comparison of parental (PCC) and bone-homing (BM1) MDA-MB-231 cells: 
Protein Name Gene UniProt 
BM1 / PCC 
Fold 
change 
Number of 
Peptides 
Mol. Weight 
[kDa] Sequence Length 
Interstitial collagenase  MMP1 P03956 22.56 12 54.006 469 
Sperm protein associated with 
the nucleus on the X 
chromosome B1  SPANXB1 Q9NS25 15.58 6 11.826 103 
Plasminogen activator inhibitor 
2  SERPINB2 P05120 15.56 12 46.596 415 
Protein EVI2B  EVI2B P34910 7.43 4 50.583 463 
Creatine kinase B-type  CKB P12277 6.92 6 42.644 381 
Regulator of G-protein 
signaling 10  RGS10 O43665 4.70 7 21.21 181 
Neutral cholesterol ester 
hydrolase 1  NCEH1 Q6PIU2 4.69 9 49.881 448 
Protein-glutamine gamma-
glutamyltransferase 2  TGM2 P21980 4.40 24 77.328 687 
Annexin A3  ANXA3 P12429 4.08 14 36.417 323 
Cell division cycle protein 20 
homolog  CDC20 Q12834 3.67 4 54.722 499 
CD44 antigen  CD44 P16070 3.22 10 81.553 742 
Formin-like protein 1  FMNL1 O95466 3.19 14 122.41 1104 
Alpha-taxilin TXLNA P40222 2.76 6 61.89 546 
Dedicator of cytokinesis 
protein 4 DOCK4 Q8N1I0 2.69 6 225.15 1966 
Niemann-Pick C1 protein NPC1 O15118 2.68 9 142.17 1278 
Membrane-associated 
progesterone receptor 
component 2  PGRMC2 O15173 2.53 7 26.17 247 
Pericentrin  PCNT O95613 2.52 6 378.08 3336 
Four and a half LIM domains 
protein 2  FHL2 Q14192 2.42 3 44.205 389 
Ferritin light chain  FTL P02792 2.38 6 20.019 175 
Vimentin VIM P08670 2.37 46 53.651 466 
Serine/threonine-protein 
phosphatase CPPED1  CPPED1 Q9BRF8 2.36 4 35.576 314 
CUB domain-containing 
protein 1  CDCP1 Q9H5V8 2.33 4 92.901 836 
Tyrosine-protein phosphatase 
non-receptor type 1  PTPN1 P18031 2.31 12 49.966 435 
Nicotinamide 
phosphoribosyltransferase  NAMPT P43490 2.29 26 55.52 491 
Xaa-Pro aminopeptidase 1  XPNPEP1 Q9NQW7 2.27 8 74.797 666 
Integrin alpha-6  ITGA6 P23229 2.25 22 126.63 1130 
Cytosolic non-specific 
dipeptidase  CNDP2 Q96KP4 2.21 20 52.878 475 
Fascin  FSCN1 Q16658 2.21 21 55.135 500 
Enoyl-CoA delta isomerase 2, 
mitochondrial  ECI2 O75521 2.16 2 43.585 394 
Coiled-coil domain-containing 
protein 124 CCDC124 Q96CT7 2.11 6 25.835 223 
Glutathione S-transferase Mu 1  GSTM1 P09488 2.04 3 25.712 218 
Cap-specific mRNA  CMTR1 Q8N1G2 2.01 5 95.32 835 
Nucleobindin-1  NUCB1 Q02818 2.00 5 53.879 461 
Adenosine kinase  ADK P55263 1.97 13 40.545 362 
Unconventional myosin-IXb  MYO9B Q13459 1.96 13 243.56 2158 
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Stathmin  STMN1 P16949 1.96 7 17.302 149 
Non-syndromic hearing 
impairment protein 5  DFNA5 O60443 1.96 6 54.554 496 
C-1-tetrahydrofolate synthase, 
cytoplasmic  MTHFD1 P11586 1.92 49 101.56 935 
Tryptophan--tRNA ligase, 
cytoplasmic  WARS P23381 1.92 15 53.165 471 
Protein CutA  CUTA O60888 1.90 2 20.925 198 
Epidermal growth factor 
receptor substrate 15-like 1  EPS15L1 Q9UBC2 1.89 9 99.606 910 
Cdc42-interacting protein 4  TRIP10 Q15642 1.88 8 68.351 601 
Mitochondrial import inner 
membrane translocase subunit 
Tim9 TIMM9 Q9Y5J7 1.88 3 10.378 89 
Neutral amino acid transporter 
B SLC1A5 Q15758 1.81 12 56.598 541 
Chloride intracellular channel 
protein 4  CLIC4 Q9Y696 1.80 17 28.772 253 
Copine-1  CPNE1 B0QZ18 1.79 12 59.717 542 
E3 ubiquitin-protein ligase 
Itchy homolog  ITCH Q96J02 1.76 4 102.8 903 
Nucleosome assembly protein 
1-like 1  NAP1L1 P55209 1.75 14 45.374 391 
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Legends to Figures in Supporting Information 
Figure S1.  Schematic showing the key steps in the SILAC proteomic approach used.   
MDA-MB-231 (MDA231) and bone-homed variant (BM) cell lines were incubated with 
media containing ‘heavy’ and ‘light’ isotopically labelled amino acids arginine (R) and lysine 
(K).  The heavy medium contained [
13
C6, 
15
N4]-L-Arginine and [
13
C6, 
15
N2]-L-Lysine, i.e. 
stable isotopes of [
12
C6, 
14
N4]-L-Arginine and [
12
C6, 
14
N2]-L-Lysine, respectively.  Two 
experiments were performed involving ‘forward’ and ‘reverse’ labelling (reciprocal labelling) 
in which the cell lines were incubated in both media types and then combined in heavy:light 
pairs in a 1:1 ratio (based on extracted protein assay) prior to separation by molecular weight 
using 1-DE.  The entire lane of gel-separated proteins was cut into equal slices (n=10).  The 
proteins in each gel slice were reduc d to peptides by enzymatic digestion (using trypsin) and 
were further separated using high-performance liquid chromatography (HPLC) and analysed 
using high-resolution mass spectrometry (MS) 
 
Figure S2: Testing antibody specificity by immunohistochemistry within FFPE-cells: 
(A) Western blotting confirmation of DOCK4 knockdown in DOCK4 miRNA 
transfected MDA-MB-231 cells, 
(B) Representative microscopy fields from FFPE-embedded bone-homing MDA-MB-
231 cells (BM1) stably transfected with either control lentivirus (Control vector) 
or DOCK4-miRNA-expressing lentivirus (DOCK4-miRNA) and subjected to 
immunohistochemical staining using the Bethyl anti-DOCK4-antibody with 
Haematoxylin counterstaining. Two representative fields are shown for each cell-
type.  
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(C) Quantification of mean cellular DAB staining level across five replicates of each 
cell-type (mean ± SEM, n = 5).             
Figure S3: Testing antibody specificity by western blotting of cell-lysates: 
(A) Full length ECL images of Western blots of 50µg total cell lysate from PCC-cells 
(lane 1) and BM1 cells (lane 2). Western blotting was performed using the Abcam 
anti-DOCK4 antibody (ab56743) as described. Tubulin loading control is also 
shown. Quantification of the normalised DOCK4 band intensity is depicted in the 
attached histogram (n = 3 replicate gels, mean band intensity ± SEM).    
(B) Full length ECL images of Western blots of 50µg total cell lysate from PCC (lane 
1) and BM1-cells (lane 2) probed with the Bethyl anti-DOCK4 antibody. Tubulin 
loading control included. Histogram depicts the quantification of the normalised 
DOCK4 band intensity (mean ± SEM, n = 3, replicate gels).  
 
 
Figure S4: Gene expression analysis of DOCK4 expression and time to bone metastasis: 
Time to bone metastasis analysis of DOCK4 expression level within breast cancer patients 
from Wang et al. with high (> 8.53) and low (< 8.53) levels of DOCK4-gene expression. 
 
Figure S5 Univariate associations of distant recurrence outcomes with biomarker 
expression for DOCK4 low and DOCK4 high. (Estimates are from Cox proportional 
hazards regressions).   
Kaplan-Meier estimates of the survival function for time to distant recurrence (DR) and 
overall survival for control and zoledronate arms for dichotomised DOCK4 low (1 and 2) and 
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high (3). Numbers 1 to 3 refer to the DOCK4 staining intensity scores. Comparisons shown 
to be significant are also significant in analyses adjusting for the effect of systemic therapy 
plan, ER status and lymph node involvement. (a) and (b): Skeletal only; (c) and (d): Skeletal 
and other; (e) and (f): Non-skeletal;  (g) and (h): First skeletal irrespective of whether other 
distant events have occurred previously (ie bone metastasis-free survival).  (i) and (j): Overall 
Survival (OS). P-values refer to the logrank test. For definitions of non-skeletal, skeletal and 
other and skeletal only see legend to Table 1. 
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Figure S1. 
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Figure S2: 
(A) 
 
(B) 
 
 
(C) 
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Figure S3: 
(A) 
 
(B) 
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Figure S4 
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Figure S5 
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Figure 1:  A and C.  Higher DOCK4 expression in BM cell type; B and D  Knock-down of DOCK4 expression 
by shRNA.  DOCK4 was confirmed to be of higher expression in BM1 cell type by Western blotting (2.0-fold 
induction, p = 0.027), and 81% and 88% knock-down of DOCK4 protein expression was achieved in PCC 
and BM1 cells, respectively.  Representative whole-gel lane images are shown.  wt = wild type (no vector 
 involvement); cv = control vector; sh = shRNA. E and F:  Invasion assay.  The ability of PCC and BM1 
cells to move through Matrigel™ matrix was assessed using a scratch-wound assay.  Significant differences 
between the control vector and DOCK4 knock-down cells were seen at the 6 and 12hr time points.      
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Figure 2. Examples of staining profiles for DOCK 4 in patients from the AZURE study.  
Composite of differential protein expression intensities for DOCK4 protein expression as revealed by IHC and 
visualised at magnification x 20.  The scoring is based on the intensity of staining in the cytoplasmic 
compartment in the tumour cells only.  Scale bar = 200µm.  
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Figure 3. Association of DOCK4 with DFS events. Kaplan-Meier estimates of the relationship between 
expression of DOCK4 and (a) non-skeletal DFS events (b) skeletal DFS events (where other distant events 
may have been recorded at the same time);  (c) solely skeletal DFS events (where no other distant event 
was recorded at the same time) and (d) any DFS events (where first event was recorded at any distant site) 
in patients in the control arm of the AZURE trial (n = 434). P-value is from the logrank test for testing 
equality of survival functions.  
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Figuire 4. Univariate associations of distant recurrence outcomes with biomarker expression in control and 
zoledronate arms. (Estimates are from Cox proportional hazards regressions) Kaplan-Meier estimates of the 
survival function for time to distant recurrence (DR) and overall survival for control and zoledronate arms. 
Numbers 1 to 3 refer to the DOCK4 staining intensity scores. These were dichotomised, ie DOCK4 low (1 and 
2); DOCK4 high (3).  Comparisons shown to be significant are also significant in analyses adjusting for the 
effect of systemic therapy plan, ER status and lymph node involvement. (a) and (b): Skeletal only; (c) and 
(d): skeletal and other; (e) and (f): Non-skeletal; (g) and (h): First skeletal irrespective of whether other 
distant events have occurred previously (ie bone metastasis-free survival).  (i) and (j): Overall Survival 
(OS). P-values refer to the logrank test. For definitions of non-skeletal, skeletal and other and skeletal only 
see legend to Table 1.  
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